Screening Protocol of Propofol Infusion Syndrome

Muzaiwirin Muzaiwirin, Arie Utariani

= http://dx.doi.org/10.20473/ijar.V2I22020.67-76
Abstract views = 201 times | downloads = 105 times

Abstract


Introduction: Propofol is often used as sedation for a long time in the ICU. The use is at risk of Propofol Infusion Syndrome (PRIS) which is characterized by arrhythmias or decreased heart function, metabolic acidosis, rhabdomyolysis, and acute renal failure. Literature Review: The pathophysiology of PRIS is due to a disturbance in cell metabolism which inhibits the transport of Free Fatty Acid (FFA) into cells and inhibits the mitochondrial respiration chain. The management of PRIS is supportive of every symptom that arises so that screening is needed as a treatment to reduce high mortality rates. Screening using creatine phosphokinase (CPK) and lactate is supporting data as an initial introduction for symptoms of PRIS. Conclusion: PRIS can occur if continuous administration of propofol > 4 mg / kg / hour. CPK levels> 5000 IU / L become a benchmark to stop propofol before the onset symptoms of PRIS. Implementation of screening protocol is very helpful for clinicians to reduce mortality in ICU due to the use of propofol.

Keywords


Propofol Infusion Syndrome; Screening Protocol; Intensive Care Unit

Full Text:

PDF

References


Miller R, Eriksson L, Fleisher L, William Y, Wiener-Kronish J, Cohen N. Millers Anesthesia. 8th edition. Saunders; 8 edition (October 28, 2014); 2015.

Bishr Haydar MD. Stoelting’s Pharmacology and Physiology in Anesthetic Practice. 5th edition. (Flood P, Rathmell JP, Shafer S, eds.). Wolters Kluwer, Philadelphia, USA, 2015; 2015.

Butterworth JF, Mackey DC, Wasnick JD. Morgan and Mikhail’s Clinical Anesthesiology. 5th edition. Mc Graw Hill; 2013.

T. J. Parke, Stevens JE, A. S. C. Rice et al. “Metabolic acidosis and fatal myocardial failure after propofol infusion in children: five case reports,.” British Medical J. 1992; 305, :613-616.

Krajčová A, Waldauf P, Anděl M, Duška F. Propofol infusion syndrome: A structured review of experimental studies and 153 published case reports. Crit Care. 2015;19(1). DOI:10.1186/s13054-015-1112-5

Notis fra Bivirkningsnaenet. Propofol (Diprivan) bivirkninger. [Adverse effects of propofol (Diprivan)]. Ugeskr Laeger 1990;152(16):1176.

Cremer OL, Moons KGM, Bouman EAC, Kruijswijk JE, De Smet AMGA, Kalkman CJ. Long-term propofol infusion and cardiac failure in adult head-injured patients. Lancet. 2001;357(9250):117-118. DOI:10.1016/S0140-6736(00)03547-9

Ahlen K, Buckley CJ, Goodale DB, Pulsford AH. The “propofol infusion syndrome”: The facts, their interpretation and implications for patient care. Eur J Anaesthesiol. 2006;23(12):990-998. DOI:10.1017/S0265021506001281

U.S. Food and Drug Administration. MedWatch. Detailed view: safety labeling changes approved by FDA Center for Drug Evaluation and Research (CDER)—February 2007. Diprivan (propofol) injectable emulsion for IV administration. 2007. 2014. http://www.fda.gov/Medwatch/SAFETY/2007/%0Afeb07.htm#Diprivan.

Barr J, Fraser GL, Puntillo K et al: Clinical practice guidelines for the management of pain, agitation, and delirium in adult patients in the intensive care unit. Crit Care Med 2013;41(1)263-306.

Masaki Y, Tanaka M NT. Physicochemical compatibility of propofol-lidocaine mixture. Anesth Analg 2003;97:1646–1651.

Vree TB1, Lagerwerf AJ, Bleeker CP de GP. Direct high-performance liquid chromatography determination of propofol and its metabolite quinol with their glucuronide conjugates and preliminary pharmacokinetics in plasma and urine of man. J Chromatogr B Biomed Sci Appl 1999 Jan 22;721(2)217-28.

Noterman J et al: Neurochirurgie. Neurochir 34161, 1988.

Mertens MJ et al. Mixed-effects Modeling of the Influence of Alfentanil on Propofol Pharmacokinetics. Anesthesiol 100795, 2004.

Leena jalota, Yung-yin NaL. Prevention of pain on injection of propofol: systematic review and meta-analysis. BMJ 2011;342d1110.

Borgeat A, Wilder-Smith OHG SP. The nonhypnotic therapeutic applications of propofol. Anesthesiol 1994;80642–656.

Avramov MN, Husain MM WP. The comparative effects of methohexital, propofol, and etomidate for electroconvulsive therapy. Anesth Analg 1995;81:596–602.

R. J. Bray. “Propofol infusion syndrome in children,” Paediatric. Anaesthesia, vol 8, no 6, pp 491–499, 1998.

Schroeppel TJ, Fabian TC, Clement LP et al. Propofol infusion syndrome: a lethal condition in critically injured patients eliminated by a simple screening protocol. Inj 2014;45245–9.

Short TG YY. Toxicity of intravenous anaesthetics. Best Pr Res Clin Anaesthesiol 2003;17(1)77-89.

Wolf A, Weir P, Segar P, Stone J SJ. Impaired fatty acid 2001;, oxidation in propofol infusion syndrome. Lancet 357(9256):606-607.

Fodale V LME. Propofol infusion syndrome: an overview of a perplexing disease. Drug Saf 2008;31(4)293-303.

Vernooy K, Delhaas T, Cremer OL et al. Electrocardiographic changes predicting sudden death in propofol-related infusion syndrome. Hear Rhythm 2006;3(2)131-137.

Otterspoor LC, Kalkman CJ CO. Update on the propofol infusion syndrome in ICU management of patients with head injury. Curr Opin Anaesthesiol 2008;21(5)544-551.

Karakitsos D, Poularas J, Kalogeromitros A KA. The propofol infusion syndrome treated with haemofiltration. Is there a time for genetic screening? Acta Anaesthesiol Scand 2007; 51(5)644-645.

Casserly B, O’Mahony E, Timm EG, Haqqie S EG, R. U. Propofol infusion syndrome: an unusual cause of renal failure. Am J Kidney Dis 2004;44(6)e98-e101.

Betrosian AP, Papanikoleou M, Frantzeskaki F DC, G. G. Myoglobinemia and propofol infusion. Acta Anaesthesiol Scand 2005;49(5)7.

Laquay N, Pouard P, Silicani MA, Vaccaroni L OG. Early stages of propofol infusion syndrome in paediatric cardiac surgery: two cases in adolescent girls. Br J Anaesth 2008; 101(6)880-881.

Schenkman KA YS. Propofol impairment of mitochondrial respiration in isolated perfused guinea pig hearts determined by reflectance spectroscopy. Crit Care Med 2000;28(1)172-177.

A.P.Maxwell, K.Linden, S.O’Donnell, P. K.Hamilton andG. E, McVeigh. “Management of hyperkalaemia,” Journal of the Royal College of Physicians of. Edinburgh, vol 43, no 3, pp 246–251, 2013.

W. Zhou, H. J. Fontenot, S.-N. Wang and RHK. “Propofol-induced alterations inmyocardial beta-adrenoceptor binding and responsiveness,.” Anesth Analg vol 89, no 3, pp 604–608, 1999.

Daniel AD, Daniel RB. Analytic Review: Propofol Infusion Syndrome in the ICU. J. of Int Care Med 2011; 26(2) 59-72.


Refbacks

  • There are currently no refbacks.


Copyright (c) 2020 Indonesian Journal of Anesthesiology and Reanimation

View My Stats

INDEXED BY:

   

 

P-ISSN: 2722-4554

E-ISSN: 2686-021X

Creative Commons Licence
This work is licensed under a Creative Commons Attribution-ShareAlike 4.0 International License.